Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease .
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease . Dialogues Clin Neurosci. 2019;21(2):177-191 Authors: Hampel H, Vergallo A, Afshar M, Akman-Anderson L, Arenas J, Benda N, Batrla R, Broich K, Caraci F, Cuello AC, Emanuele E, Haberkamp M, Kiddle SJ, Lucía A, Mapstone M, Verdooner SR, Woodcock J, Lista S Abstract Alzheimer's disease (AD)-a complex disease showing multiple pathomechanistic alterations-is triggered by nonlinear dynamic interactions of genetic/epigenetic and environmental risk factors, which, ultimately, converge into a biologically heterogeneous disease. To tackle the burden of AD during early preclinical stages, accessible blood-based biomarkers are currently being developed. Specifically, next-generation clinical trials are expected to integrate positive and negative predictive blood-based biomarkers into study designs to evaluate, at the individual level, target druggability and potential drug resistance mechanisms. In this scenario, systems biology holds promise to accelerate validation and qualification for clinical trial contexts of use-including proof-of-mechanism, patient selection, assessment of treatment efficacy and safety rates, and prognostic evaluation. Albeit in their infancy, systems biology-based approaches are poised to identify relevant AD "signatures" through multifactorial and interindividual variability, allowing us to decipher disease pathophysiology a...
Publication date: 18 January 2020Source: New Scientist, Volume 245, Issue 3265Author(s): Alice Klein
DEMENTIA is a progressive neurological condition that mainly affects people over the of 65, although it is not a natural part of ageing. Spotting the early warning signs is key to maintaining quality of life for as long as possible. A recent study suggests that Alzheimer ’s disease, the most common form of dementia, can be signalled by a change in your eyes.
Authors: Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D Abstract INTRODUCTION: We evaluated the clinical profile of the orexin receptor antagonist suvorexant for treating insomnia in patients with mild-to-moderate probable Alzheimer's disease (AD) dementia. METHODS: Randomized, double-blind, 4-week trial of suvorexant 10 mg (could be increased to 20 mg based on clinical response) or placebo in patients who met clinical diagnostic criteria for both probable AD dementia and insomnia. Sleep was assessed by overnight polysomnography in a sleep laboratory. The primar...
Authors: Fossel M PMID: 31943780 [PubMed - as supplied by publisher]
The IPDGC (The International Parkinson Disease Genomics Consortium) and EADB (Alzheimer Disease European DNA biobank) are listed correctly as an author to the article, however, they were incorrectly listed more than once.
ConclusionThese results demonstrate that vortioxetine may improve cognitive impairment in 5 ×FAD mice. The role in cognitive improvement may be related to the beneficial effects of vortioxetine on synaptic function.
CONCLUSIONS: ¹⁸F-FC119S PET provides high sensitivity and specificity in detecting AD and therefore may be considered a useful diagnostic tool for AD. PMID: 31942769 [PubMed]
Publication date: Available online 17 January 2020Source: Life SciencesAuthor(s): Hongmei Wang, Ting Zhang, Xuhua Ge, Jingjiong Chen, Yuwu Zhao, Jianliang FuAbstractAimsMitochondrial dysfunction is an early prominent feature of Alzheimer's disease (AD). In the present study, we sought to investigate whether defective mitophagy is tightly related to amyloid-β (Aβ)-induced mitochondrial dysfunction.Main methodsImmunofluorescence, western blot and transmission electron microscopy were used to examine mitophagy. Mitochondrial membrane potential was assessed using the JC-1 dye. Mitochondrial ROS was detected using Mit...
Chem. Commun., 2020, Advance Article DOI: 10.1039/C9CC09233A, CommunicationGuanglei Lv, Anyang Sun, Minqi Wang, Peng Wei, Ruohan Li, Tao Yi Detection of A β protofibrils at the early stage of Alzheimer's disease was realized by a novel near-infrared probe (DCM-AN) based on dicyanomethylene-4H-pyran. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry